Compare Expeditors International of Wshngtn Inc (EXPD) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Heron Therapeutics Inc — how do they compare? Expeditors International of Wshngtn Inc trades at $193.74 (market cap $24.81B), while Heron Therapeutics Inc trades at $0.37 (market cap $68.01M). The key difference: Expeditors International of Wshngtn Inc is far larger — about 364.8× Heron Therapeutics Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.85% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 43 Days and Heron Therapeutics Inc for 35 Days on average.
| EXPD | HRTX | |
|---|---|---|
Market Cap | $24.81B | $68.01M |
Volume | 832,787 | 1,891,941 |
Sector | Industrials | Health |
52-Week High | $194.12 | $1.49 |
52-Week Low | $113.13 | $0.27 |
Typical Hold Time | 43 Days | 35 Days |
Enterprise Value | $24.34B | $174.75M |
Dividend Yield | 0.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $190.85, down 0.5% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.03 surpassing the $1.69 estimate. Revenue for 2025 reached $11.07 billion, with a net income margin of 7.63% and robust ROE of 42.6%. Recent news highlights efficiency initiatives and resilient airfreight demand as positive catalysts.
The outlook is mixed; solid profitability and earnings momentum support upside, but the stock trades above the consensus price target of $179.43, with analysts predominantly neutral (63.64% Hold). Key risks include freight market volatility and execution challenges. Institutional activity shows mixed signals, with some firms increasing stakes while others reduce positions.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
